衰弱是一种以恢复力和生理储备下降为特征的老年综合征，对老年人的预后和治疗有显着影响，特别是在外科和肿瘤护理的背景下。 概述老年肾肿块患者治疗中的衰弱评估/肾细胞癌（RCC），重点关注其对诊断检查、治疗决策和临床结果的影响。对文献进行了叙述性回顾，重点关注衰弱定义、评估工具及其在老年肿瘤学中的应用，应用于RCC 领域。总结了有关衰弱的预后价值、其对治疗结果的影响和潜在干预措施的相关研究。衰弱是一个不良的预后因素，可以影响局部和转移性肾细胞癌的治疗决策。老年筛查工具 8 (G8) 和 Mini-COG 测试等筛查工具可以帮助临床医生选择老年患者（即年龄≥65 岁），由专门的老年病学家进行进一步全面的老年评估 (CGA)。 CGA 提供了对患者进行风险分层并指导后续治疗途径的见解。因此，老年科医生参与多学科肿瘤委员会成为解决体弱患者复杂需求和优化临床结果的重要优先事项。在此，我们提出专门的护理途径，作为在 RCC 临床实践和研究中实施衰弱评估的关键第一步。衰弱已成为影响老年 RCC 患者治疗和结果的关键因素。老年科医生参与诊断和治疗途径代表了一种筛查和评估虚弱的务实方法，根据整体患者风险分层促进个体化治疗决策。虚弱，即弹性和生理储备的下降，影响老年肾细胞患者的治疗决策和结果癌症，指导个性化护理。在这篇综述中，我们重点关注筛查年龄超过 65 岁、疑似肾细胞癌的肾肿块患者是否虚弱的实用策略，以及将老年输入纳入患者和肿瘤相关因素之外的个性化管理算法。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Frailty, a geriatric syndrome characterized by decreased resilience and physiological reserve, impacts the prognosis and management of older adults significantly, particularly in the context of surgical and oncological care.To provide an overview of frailty assessment in the management of older patients with a renal mass/renal cell carcinoma (RCC), focusing on its implications for diagnostic workup, treatment decisions, and clinical outcomes.A narrative review of the literature was conducted, focusing on frailty definitions, assessment tools, and their application in geriatric oncology, applied to the field of RCC. Relevant studies addressing the prognostic value of frailty, its impact on treatment outcomes, and potential interventions were summarized.Frailty is a poor prognostic factor and can influence decision-making in the management of both localized and metastatic RCC. Screening tools such as the Geriatric Screening Tool 8 (G8) and the Mini-COG test can aid clinicians to select older patients (ie, aged ≥65 yr) for a further comprehensive geriatric assessment (CGA) performed by dedicated geriatricians. The CGA provides insights to risk stratify patients and guide subsequent treatment pathways. As such, the involvement of geriatricians in multidisciplinary tumor boards emerges as an essential priority to address the complex needs of frail patients and optimize clinical outcomes. Herein, we propose a dedicated care pathway as a first key step to implement frailty assessment in clinical practice and research for RCC.Frailty has emerged as a crucial factor influencing the management and outcomes of older patients with RCC. Involvement of geriatricians in diagnostic and therapeutic pathways represents a pragmatic approach to screen and assess frailty, fostering individualized treatment decisions according to holistic patient risk stratification.Frailty, a decline in resilience and physiological reserve, influences treatment decisions and outcomes in elderly patients with renal cell carcinoma, guiding personalized care. In this review, we focused on pragmatic strategies to screen patients with a renal mass suspected for renal cell carcinoma, who are older than 65 yr, for frailty and on personalized management algorithms integrating geriatric input beyond patient- and tumor-related factors.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.